CoChat
Sign Up
Cited by 89Fatty Acid Research and HealthDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Association of fish oil supplement use with preservation of brain volume and cognitive function

Open access
Daiello, Lori A., Gongvatana, Assawin, Dunsiger, Shira, Cohen, Ronald A., Ott, Brian R., Alzheimer's Disease Neuroimaging Initiative·2015·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2014.02.005PMC PMC4829435
Open this paper in CoChat — free account

Abstract

Objective: The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults. Methods: We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes. Results: FOS use during follow‐up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini‐Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE ε4–negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2014.02.005

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only patients with mild cognitive impairment who do not have the ε4 allele of APOE had better cognitive outcomes after fish oil treatment.

    “However, it seems that only patients with mild cognitive impairment who do not have ε4 allele of the APOE gene had better cognitive outcomes after treatment with fish oil [185].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [185]

    Results §3.3.1 (page unavailable) reports that the association between fish-oil supplement use and better cognitive scores remained significant only in APOE ε4 noncarriers. But Results §3.3.2 finds significant cognitive associations only among participants with normal cognition at baseline, not those with mild cognitive impairment. The study assessed supplement use rather than testing a fish-oil treatment. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Laditka JN Laditka SB Tait EM Tsulukidze MM Use of dietary supplements for cognitive health: results of a national survey of adults in the United States Am J Alzheimers Dis Other Demen 2012 27 55 64 22323831 PMC10697390
  2. [2]van Gelder BM Tijhuis M Kalmijn S Kromhout D Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study Am J Clin Nutr 2007 85 1142 7 17413117
  3. [3]Barberger-Gateau P Jutand MA Letenneur L Larrieu S Tavernier B Berr C Correlates of regular fish consumption in French elderly community dwellers: data from the Three-City study Eur J Clin Nutr 2005 59 817 25 15900310
  4. [4]Huang TL Zandi PP Tucker KL Fitzpatrick AL Kuller LH Fried LP Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4 Neurology 2005 65 1409 14 16275829
  5. [6]Barberger-Gateau P Letenneur L Deschamps V Peres K Dartigues JF Renaud S Fish, meat, and risk of dementia: cohort study BMJ 2002 325 932 3 12399342 PMC130057
  6. [7]Yurko-Mauro K Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline Curr Alzheimer Res 2010 7 190 6 20088810
  7. [8]Sinn N Milte CM Street SJ Buckley JD Coates AM Petkov J Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial Br J Nutr 2011 1 12 21929835
  8. [9]Sydenham E Dangour AD Lim WS Omega 3 fatty acid for the prevention of cognitive decline and dementia Sao Paulo Med J 2012 130 419 23338743 PMC10522313
  9. [10]van de Rest O Geleijnse JM Kok FJ van Staveren WA Dullemeijer C Olderikkert MG Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial Neurology 2008 71 430 8 18678826
  10. [11]Dangour AD Whitehouse PJ Rafferty K Mitchell SA Smith L Hawkesworth S B-vitamins and fatty acids in the prevention and treatment of Alzheimer’s disease and dementia: a systematic review J Alzheimers Dis 2010 22 205 24 20847412
  11. [12]Stough C Downey L Silber B Lloyd J Kure C Wesnes K The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population Neurobiol Aging 2012 33 e821 3 21531481
  12. [13]Quinn JF Raman R Thomas RG Yurko-Mauro K Nelson EB Van Dyck C Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA 2010 304 1903 11 21045096 PMC3259852
  13. [14]Chiu CC Su KP Cheng TC Liu HC Chang CJ Dewey ME The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study Prog Neuropsychopharmacol Biol Psychiatry 2008 32 1538 44 18573585
  14. [15]Terano T Fujishiro S Ban T Yamamoto K Tanaka T Noguchi Y Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases Lipids 1999 34 Suppl S345 6 10419198
  15. [16]Mazereeuw G Lanctot KL Chau SA Swardfager W Herrmann N Effects of omega-3 fatty acids on cognitive performance: a meta-analysis Neurobiol Aging 2012 33 e1417 29 22305186
  16. [17]Freund-Levi Y Eriksdotter-Jonhagen M Cederholm T Basun H Faxen-Irving G Garlind A Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial Arch Neurol 2006 63 1402 8 17030655
  17. [19]Landau SM Harvey D Madison CM Koeppe RA Reiman EM Foster NL Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI Neurobiol Aging 2011 32 1207 18 19660834 PMC2891865
  18. [20]Swaminathan S Kim S Shen L Risacher SL Foroud T Pankratz N Genomic copy number analysis in Alzheimer’s disease and mild cognitive impairment: an ADNI study Int J Alzheimers Dis 2011 2011 729478 21660214 PMC3109875
  19. [21]Mueller SG Weiner MW Thal LJ Petersen RC Jack CR Jagust W Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimers Dement 2005 1 55 66 17476317 PMC1864941
  20. [25]Zeger SL Liang KY Longitudinal data analysis for discrete and continuous outcomes Biometrics 1986 42 121 30 3719049
  21. [26]Zeger SL Liang KY Albert PS Models for longitudinal data: a generalized estimating equation approach Biometrics 1988 44 1049 60 3233245
  22. [27]Bowman GL Silbert LC Howieson D Dodge HH Traber MG Frei B Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging Neurology 2012 78 241 9 22205763 PMC3280054
  23. [28]Tan ZS Harris WS Beiser AS Au R Himali JJ Debette S Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging Neurology 2012 78 658 64 22371413 PMC3286229
  24. [29]Samieri C Maillard P Crivello F Proust-Lima C Peuchant E Helmer C Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe Neurology 2012 79 642 50 22855869
  25. [30]Rowe CC Ellis KA Rimajova M Bourgeat P Pike KE Jones G Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 2010 31 1275 83 20472326
  26. [31]Rodrigue KM Kennedy KM Devous MD Sr Rieck JR Hebrank AC Diaz-Arrastia R β-Amyloid burden in healthy aging: regional distribution and cognitive consequences Neurology 2012 78 387 95 22302550 PMC3280058
  27. [32]Whalley LJ Deary IJ Starr JM Wahle KW Rance KA Bourne VJ n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood Am J Clin Nutr 2008 87 449 54 18258638
  28. [34]Cunnane SC Chouinard-Watkins R Castellano CA Barberger-Gateau P Docosahexaenoic acid homeostasis, brain aging and Alzheimer’s disease: can we reconcile the evidence? Prostaglandins Leukot Essent Fatty Acids 2013 88 61 70 22575581
  29. [35]Hennebelle M Plourde M Chouinard-Watkins R Castellano CA Barberger-Gateau P Cunnane SC Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline Proc Nutr Soc 2013 1 7 24103099
  30. [36]Chouinard-Watkins R Rioux-Perreault C Fortier M Tremblay-Mercier J Zhang Y Lawrence P Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoE epsilon4 allele Br J Nutr 2013 110 1751 9 23631810
  31. [37]Barberger-Gateau P Raffaitin C Letenneur L Berr C Tzourio C Dartigues JF Dietary patterns and risk of dementia: the Three-City cohort study Neurology 2007 69 1921 30 17998483
  32. [38]Beydoun MA Kaufman JS Satia JA Rosamond W Folsom AR Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study Am J Clin Nutr 2007 85 1103 11 17413112
  33. [39]Calandria JM Mukherjee PK de Rivero Vaccari JC Zhu M Petasis NA Bazan NG Ataxin-1 poly(Q)-induced proteotoxic stress and apoptosis are attenuated in neural cells by docosahexaenoic acid-derived neuroprotectin D1 J Biol Chem 2012 287 23726 39 22511762 PMC3390647
  34. [40]Lukiw WJ Bazan NG Inflammatory, apoptotic, and survival gene signaling in Alzheimer’s disease. A review on the bioactivity of neuroprotectin D1 and apoptosis Mol Neurobiol 2010 42 10 6 20414817
  35. [41]Zhao Y Calon F Julien C Winkler JW Petasis NA Lukiw WJ Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer’s disease models PLoS One 2011 6 e15816 21246057 PMC3016440
  36. [42]Morris MC Nutritional determinants of cognitive aging and dementia Proc Nutr Soc 2012 71 1 13 22067138

Cited by

Sorted by citations

Authors
Daiello, L. A., Gongvatana, A., Dunsiger, S., Cohen, R. A., Ott, B. R., & Initiative, A. D. N.
Affiliations
  • Brown University (US)
  • Miriam Hospital (US)
Corresponding author
Daiello, Lori A.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-06-18
Volume
11
Issue
2
Pages
226-235
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2014.02.005
PMC
PMC4829435
OpenAlex
W2170907553
Cited by
89
References
6
Citations by year
2026: 3 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 11 · 2015: 7 · 2014: 1
FWCI
8.69
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Alzheimer's Disease Neuroimaging Initiative (U01 AG024904)
  • Abbott Fund
  • Alzheimer's Drug Discovery Foundation
  • Amorfix Life Sciences
  • AstraZeneca
  • Bayer HealthCare
  • BioClinica
  • Biogen Idec
  • Bristol-Myers Squibb
  • Eisai
  • Roche
  • Genentech
  • GE Healthcare
  • Innogenetics
  • Janssen Research and Development
  • Medpace
  • Merck
  • Meso Scale Diagnostics
  • Novartis Pharmaceuticals Corporation
  • Servier
  • Synarc
  • Takeda Pharmaceutical Company
  • Canadian Institutes of Health Research
  • Foundation for the National Institutes of Health
  • Northern California Institute for Research and Education (P30 AG010129, K01 AG030514)
  • Agency for Healthcare Research and Quality (K08 HS017735)
  • National Institute on Alcohol Abuse and Alcoholism (P01AA019072, R00AA020235, R01NS080655)
  • National Cancer Institute (R03 CA153942, R01 CA155381)
  • National Institute of Nursing Research (R01 NR011295)
  • National Center for Complementary and Alternative Medicine (R01AT006948)
  • National Institute on Drug Abuse (R01 DA021729, R34 DA031057)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R18 DK075371)
  • National Institutes of Health (R01 HL089311, U01 CA1503878, R34 DA031057‐02, P01 AA019072, R01 NS036524, R01 HL084178, R01 DA020725, R56 DK075119, R01 MH074368)
  • Pfizer
  • Baxter International
  • Alzheimer's Association
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
fish oil supplements, cognitive decline
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Atrophy, Brain, Female, Fish Oils, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Organ Size, Retrospective Studies, Cohort Studies, Treatment Outcome, Neuroprotective Agents, Apolipoprotein E4, Cognitive Dysfunction, Gray Matter

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review